EBITDA Margin % is calculated as EBITDA divided by its Revenue. Axsome Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-61.0 Mil. Axsome Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $191.2 Mil. Therefore, Axsome Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -31.90%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Axsome Therapeutics EBITDA Margin % Related Terms
Axsome Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Axsome Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXSM vs IONS, EXEL, MDGL: EBITDA Margin % Comparison
For the Biotechnology subindustry, Axsome Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axsome Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics (AXSM) has a EBITDA Margin % of -31.90% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Axsome Therapeutics and its competitors. According to the industry distribution chart, Axsome Therapeutics ranks #399 out of 944 companies in the Biotechnology industry, placing it in the top 42.3%.
Is Axsome Therapeutics' EBITDA Margin % too high?
Axsome Therapeutics' current EBITDA Margin % is -31.90%. Based on the distribution chart, Axsome Therapeutics ranks #399 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' EBITDA Margin % compare to IONS and EXEL?
According to the Biotechnology industry distribution chart, Axsome Therapeutics ranks #399 out of 944 companies for EBITDA Margin %. This puts Axsome Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current EBITDA Margin % is -31.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $220.41, compared to a current price of $241.67 — trading 9.6% above its estimated fair value. The current EBITDA Margin % is -31.90%. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current EBITDA Margin % is -31.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axsome Therapeutics (AXSM) Overvalued in 2026?
Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued.
The current stock price of $241.67 is trading 9.6% above its estimated GF Value™ of $220.41.
GuruFocus considers Axsome Therapeutics to be Fairly Valued.
Key valuation signals for AXSM:
EBITDA Margin %: -31.90%
GF Value™: $220.41 vs. price of $241.67 (9.6% above fair value)
No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score
Get the complete analysis for AXSM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXSM has been successfully added to your 
